Since joining Kirkland, Kevin has been involved in the following representative matters:
- Akero Therapeutics in its sale to Novo Nordisk for up to $5.2 billion
Prior to joining Kirkland, Kevin was involved in the following representative matters:
- Alcon in its acquisition of LumiThera Inc.
- Vertex Pharmaceuticals in its $4.9 billion acquisition of Alpine Immune Sciences
- Ambrx Biopharma in its $2 billion acquisition by Johnson & Johnson
- Mirati Therapeutics in its sale to Bristol Myers Squibb for up to $5.8 billion
- Apria in its $1.45 billion acquisition by Owens & Minor
- CorePoint Lodging in its $1.5 billion acquisition by a joint venture between affiliates of Highgate and Cerberus Capital Management
- Hilton Grand Vacations in connection with the financing for its acquisition of Diamond Resorts for $1.4 billion
- EQT in connection with the financing for its acquisition of First Student and First Transit for $4.6 billion
